Was tut sich bei Cepheid? - 500 Beiträge pro Seite

[NOBODY_III]

18.10.2004 13:09:
Cepheid to Present at Rodman & Renshaw Techvest 6th Annual Healthcare Conference

SUNNYVALE, Calif., Oct. 18 /PRNewswire-FirstCall/ -- Cepheid (Nachrichten) will present at the Rodman and Renshaw Techvest 6th Annual Healthcare Conference being held at the Waldorf-Astoria Hotel in New York, New York, October 26-28, 2004. Chief Executive Officer John L. Bishop and Chief Financial Officer John R. Sluis will present at 10:25 a.m. Eastern on Thursday, October 28, 2004.

Rodman and Renshaw will provide a live webcast of the audio presentation available at the following address: http://www.wallstreetwebcasting.com/webcast/rrshq4/cphd/. The webcast, along with accompanying presentation slides, may also be accessed on the Company`s web site at http://www.cepheid.com/ under Investors: Events: Webcasts and Presentations. A replay of the webcast presentation will be available for 90 days at both sites.

About Cepheid

Cepheid , based in Sunnyvale, Calif., is a leading developer, manufacturer and marketer of fully integrated systems that enable genetic assessment when and where it is needed. Founded in 1996, the company is commercializing its technology and products worldwide for research, medical, and industrial applications requiring assessment of the human genome, infectious disease and biothreat agents. See http://www.cepheid.com/ for more information.

For further information, please contact John L. Bishop, CEO, [phone], [e-mail], or John R. Sluis, CFO, [phone], [e-mail], both of Cepheid; or media, Tim Grace, [phone], [e-mail], or investor/analyst information, Tricia Ross, [phone], [e-mail], both of Financial Relations Board, for Cepheid.

Cepheid

[NOBODY_III]

27.10.2004 13:08:
Cepheid Named to the 2004 Deloitte Technology Fast 500

SUNNYVALE, Calif., Oct. 27 /PRNewswire-FirstCall/ -- Cepheid (Nachrichten) announced that it has been named on the 2004 Deloitte Technology Fast 500, a ranking of the 500 fastest growing technology companies in North America. Rankings are based on percentage revenue growth over five years, from 1999-2003.

"We appreciate being recognized as a member of this fast growing group of companies," said Cepheid`s CEO, John L. Bishop. "We expect to continue to see growth driven by our biothreat business in the near term and our clinical business in the medium and long term."

"Growing the top line enough to make the Deloitte Technology Fast 500 is especially meaningful during tough economic times for the technology sector," said Mark A. Evans, national managing partner of Deloitte`s Technology, Media & Telecommunications Group. "We congratulate Cepheid on becoming one of the 500 fastest growing technology companies in North America."

The Fast 500 list is compiled from Deloitte`s 19 regional North American Fast 50 programs, nominations submitted directly to the Fast 500, and public company database research. To qualify for the Fast 500, entrants must have had 1999 operating revenues of at least $50,000 USD for the United States or $75,000 CD for Canada; and 2003 operating revenues must be at least $1 million USD or CD.

Entrants must also be public or private companies headquartered in North America and must be a "technology company," defined as a company that owns proprietary technology that contributes to a significant portion of the company`s operating revenues; or devotes a significant proportion of revenues to the research and development of technology. Using other companies` technology in a unique way does not qualify.

About Cepheid

Cepheid , based in Sunnyvale, Calif., is a leading developer, manufacturer and marketer of fully integrated systems that enable genetic assessment when and where it is needed. Founded in 1996, the company is commercializing its technology and products worldwide for research, medical, and industrial applications requiring assessment of the human genome, infectious disease and biothreat agents. See http://www.cepheid.com/ for more information.

About Deloitte

Deloitte refers to one or more of Deloitte Touche Tohmatsu, a Swiss Verein, its member firms, and their respective subsidiaries and affiliates. Deloitte Touche Tohmatsu is an organization of member firms around the world devoted to excellence in providing professional services and advice, focused on client service through a global strategy executed locally in nearly 150 countries. With access to the deep intellectual capital of 120,000 people worldwide, Deloitte delivers services in four professional areas -- audit, tax, consulting, and financial advisory services -- and serves more than one- half of the world`s largest companies, as well as large national enterprises, public institutions, locally important clients, and successful, fast-growing global growth companies. Services are not provided by the Deloitte Touche Tohmatsu Verein, and for regulatory and other reasons, certain member firms do not provide services in all four professional areas.

As a Swiss Verein (association), neither Deloitte Touche Tohmatsu nor any of its member firms has any liability for each other`s acts or omissions. Each of the member firms is separate and independent legal entity operating under the names "Deloitte," "Deloitte & Touche," "Deloitte Touche Tohmatsu," or other related names.

In the U.S., Deloitte & Touche USA LLP is the member firm of Deloitte Touche Tohmatsu, and services are provided by the subsidiaries of Deloitte & Touche USA LLP (Deloitte & Touche LLP, Deloitte Consulting LLP, Deloitte Tax LLP, and their subsidiaries) and not by Deloitte & Touche USA LLP. The subsidiaries of the U.S. member firm are among the nation`s leading professional services firms, providing audit, tax, consulting, and financial advisory services through nearly 30,000 people in more than 80 cities. Known as employers of choice for innovative human resources programs, they are dedicated to helping their clients and their people excel. For more information, please visit the U.S. member firm`s website at http://www.deloitte.com/us.

This press release contains forward-looking statements that are not purely historical regarding Cepheid`s or its management`s intentions, beliefs, expectations and strategies for the future, including those relating to growth of specified markets. Because such statements deal with future events, they are subject to various risks and uncertainties, and actual results could differ materially from the company`s current expectations. Factors that could cause actual results to differ materially include risks and uncertainties such as those relating to: the scope and timing of actual USPS funding and deployment of the BDS; the rate of environmental testing using the BDS conducted by the USPS, whether the BDS performs to specifications; development and manufacturing problems; our ability to successfully obtain regulatory approvals and introduce new products in the clinical market; the performance and market acceptance of new products; the impact of competitive products and pricing; and underlying market conditions worldwide. Readers should also refer to the section entitled "Risk Factors" in Cepheid`s Annual Report on Form 10-K for 2003 and "Factors that Might Affect Future Results" in its most recent quarterly report on Form 10-Q, each filed with the Securities and Exchange Commission.

All forward-looking statements and reasons why results might differ included in this release are made as of the date of this press release, based on information currently available to Cepheid, and Cepheid assumes no obligation to update any such forward-looking statement or reasons why results might differ.

CONTACTS: At the Company: John L. Bishop John R. Sluis CEO, Cepheid CFO, Cepheid 408-541-4191 408-541-4191 [e-mail] [e-mail] At Financial Relations Board: Tim Grace Tricia Ross Media Contact Investor/Analyst Information 312-640-6667 617-520-7064 [e-mail] [e-mail]

[NOBODY_III]

02.11.2004 22:04:
Cepheid Reports Third Quarter and Nine Months 2004 Results

SUNNYVALE, Calif., Nov. 2 /PRNewswire-FirstCall/ -- Cepheid (Nachrichten) today announced financial results for the quarter and nine months ended September 30, 2004.

Product sales for the quarter ended September 30, 2004 increased 190% to approximately $13.4 million from approximately $4.6 million for the corresponding prior year period while product sales for the nine months period ended September 30, 2004 increased 179% to approximately $30.6 million from $11.0 million for the corresponding prior year period. The increase in product sales for both the quarter and nine months ended September 30, 2004 as compared to the corresponding prior year periods was due to a 848% and 551% increase, respectively, in reagent and disposable sales and to a 98% and 119% increase, respectively, in instrument sales.

Total revenues for the quarter ended September 30, 2004 increased 162% to approximately $14.1 million compared to approximately $5.4 million for the corresponding prior year period, while total revenues for the nine months ended September 30, 2004 increased 146% to $32.6 million from $13.3 million for the corresponding prior year period. The increase in total revenue for both the quarter and nine months ended September 30, 2004 as compared to the corresponding prior year periods was due to the increase in product sales, which was driven in large part by sales related to the United States Postal Service (USPS) Bio-hazard Detection System (BDS), and, to a lesser extent, Life Sciences and Clinical Genetic Assessment product sales. Other revenues of $0.6 million and $2.1 million for the quarter and nine months ended September 30, 2004, respectively, was primarily derived from the amortization of up-front license fees in connection with the Company`s collaboration with bioMerieux.

Gross Margin Dollars on product sales (total product sales less cost of product sales) for the quarter and nine months ended September 30, 2004 increased by 218% and 208%, respectively, as compared to the corresponding prior year periods. The gross margin percentage on product sales for the quarter ended September 30, 2004 was 44% as compared to 40% for the corresponding prior year period and increased to 46% for the nine months ended September 30, 2004 as compared to 41% for the corresponding prior year period. The increase in product gross margin in the quarter and nine months ended September 30, 2004, as compared to the corresponding prior year periods was primarily due to a change in product mix to higher gross margin products, partially offset by the increase in royalty and license costs resulting from the recent license agreements with Applera Corporation (Applera) and F. Hoffmann-La Roche Ltd. (Roche). Gross margin on product sales for future quarters is expected to continue to be impacted by higher royalties related to these license arrangements and is expected to be consistent with the product gross margin of 45% achieved for the full year 2003.

Net loss for the quarter and nine months ended September 30, 2004 was approximately $2.9 million, or $0.07 per share and $10.8 million, or $0.26 per share, respectively, compared to a net loss of approximately $3.9 million, or $0.11 per share and $13.0 million, or $0.40 per share for the corresponding prior year periods.

"Based on the completion of our previously announced license arrangements with Applera, through Applied Biosystems (ABI) and Celera Diagnostics, and with Roche, the Company initiated during the quarter shipment of the first of our ASR products which identifies B. pertussis, followed by our second ASR product which identifies HSV in October," stated John Bishop, Cepheid`s Chief Executive Officer. "We further expect to initiate shipment of up to four additional ASR products before the end of the year."

"Sales within the Clinical market segment continue to grow with additional institutions adopting GBS testing utilizing the IDI-Step B product on the SmartCycler. As a subsequent event, in October Infectio Diagnostics, Inc. (IDI) announced that it was merging with GeneOhm Sciences, of San Diego. We do not expect the merger to affect our non-exclusive distribution rights nor license rights to IDI`s GBS, MRSA and potential VRE products. IDI began shipments of the IDI-MRSA product for use on the SmartCycler in October."

"Deployment of the Northrop Grumman BDS within various processing centers of the USPS continues to progress. BDS unit installations have been completed at over 35 different USPS sites. We expect approximately 700 BDS units to be installed by the completion of phase 1 in the first quarter of 2005. The systems and the test cartridges continue to perform well. We expect there will be a phase 2 and continue to expect to be notified concerning the timing and magnitude of the phase 2 program either at the end of the fourth quarter this year or in early 2005. We currently do not expect to see an interruption in deployment of BDS units upon the completion of phase 1 and the initiation of phase 2."

"We continued to expand our worldwide distribution of products into the Life Sciences market with the announcement of a new distributor in China during the quarter."

2004 Outlook

Commenting on Cepheid`s outlook for the remainder of 2004, Mr. Bishop stated:

"As previously stated, we expect to see continued growth in the Life Sciences and Clinical Genetic Assessment markets. We expect to initiate shipment of up to four additional ASR products which identify infectious disease organisms on the SmartCycler System in the fourth quarter. Further, we expect to be in clinical trials for our first 510k product, for Group-B Strep (GBS) on the GeneXpert System. Market launch of the GeneXpert GBS is expected in the first half of 2005."

"We are increasing our expected range of 2004 product sales to, $46.0 million to $48.0 million, based on Phase I sales for the USPS program and sales expected from other existing and new products. We expect our gross profit margin on product sales for 2004 to be consistent with that achieved in 2003 at 45%. Based on an increase in R&D investment to accelerate delivery of our ASR and Clinical products and manufacturing scale up variances, we now expect our 2004 net loss to be in the range of $13.7 million to $14.7 million or $0.33 to $0.35 per share based on actual weighted average shares outstanding of 41.9 million as of September 30, 2004."

As of September 30, 2004, the Company had $58.2 million in unrestricted cash.

Conference Call Information

Cepheid`s CEO, John Bishop, and Senior V.P. and CFO, John Sluis will host a conference call today at 4:30 pm (Eastern) to discuss Cepheid`s financial results, business highlights and outlook. The call will be simultaneously broadcast over the Internet. Interested participants and investors may access the teleconference call by dialing 800-257-7063 (domestic) or 303-275-2170 (international). There will also be a live webcast of the call on the Investor Relations section of Cepheid`s web site at http://www.cepheid.com/." target="_blank" rel="nofollow ugc noopener">http://www.cepheid.com/. Web participants are encouraged to go to the web site at least 15 minutes prior to the start of the call to register, download, and install any necessary audio software.

After the live webcast, the call will remain available on Cepheid`s website, http://www.cepheid.com/," target="_blank" rel="nofollow ugc noopener">http://www.cepheid.com/, for 12 months. A replay of the conference call will be available at 800-405-2236 (domestic) or 303-590-3000 (international) through November 9, 2004; the conference ID is 11013887. The replay will be available after 6:30 pm (Eastern).

About Cepheid

Cepheid , based in Sunnyvale, Calif., is a leading developer, manufacturer and marketer of fully integrated systems that enable genetic assessment when and where it is needed. Founded in 1996, the company is commercializing its technology and products worldwide for research, medical, and industrial applications requiring assessment of the human genome, infectious disease and biothreat agents. See http://www.cepheid.com/ for more information.

This press release contains forward-looking statements that are not purely historical regarding Cepheid`s or its management`s intentions, beliefs, expectations and strategies for the future, including those relating to future product releases, future revenues, future gross margin, future net losses and other financial data, the status of the USPS BDS program, contractual relationships and business prospects. Because such statements deal with future events, they are subject to various risks and uncertainties, and actual results could differ materially from the company`s current expectations. Factors that could cause actual results to differ materially include risks and uncertainties such as those relating to: the scope and timing of actual USPS funding and deployment of the BDS; uncertainties relating to the timing of any approval of future deployments by government agencies; the rate of environmental testing using the BDS conducted by the USPS, which will affect the amount of consumable products sold, whether the BDS performs to specifications; unforeseen research, development and manufacturing problems, including with respect to the GeneXpert system and reagents; unforeseen manufacturing costs; the need for additional licenses for new tests and other products and the terms of such licenses; our ability to successfully commercialize our stand-alone GeneXpert system; lengthy sales cycles in certain markets; our ability to successfully obtain regulatory approvals and introduce new products in the clinical market; the performance and market acceptance of new products; our reliance on distributors to market, sell our products; the occurrence of unforeseen expenditures, acquisitions or other transactions; the effect of acquisitions in our industry on relationships with partners; our success in increasing direct sales; the impact of competitive products and pricing; our ability to manage geographically-dispersed operations; and underlying market conditions worldwide. Readers should also refer to the section entitled "Risk Factors" in Cepheid`s Annual Report on Form 10-K for 2003 and "Factors that Might Affect Future Results" in its most recent quarterly report on Form 10-Q, each filed with the Securities and Exchange Commission.

All forward-looking statements and reasons why results might differ included in this release are made as of the date of this press release, based on information currently available to Cepheid, and Cepheid assumes no obligation to update any such forward-looking statement or reasons why results might differ.

For further information please contact: John L. Bishop, CEO, [e-mail], or John R. Sluis, CFO, [e-mail], both of Cepheid, [phone]; or media, Tim Grace, [phone], [e-mail], or investors/analysts, Tricia Ross, [phone], [e-mail], both of Financial Relations Board for Cepheid.

(FINANCIAL STATEMENTS FOLLOW) CEPHEID CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (in thousands, except per share data) Quarter Ended Nine Months Ended September 30, September 30, 2004 2003 2004 2003 Revenues: Instrument sales $8,064 $4,074 $20,648 $9,433 Reagent and disposable sales 5,385 568 9,918 1,523 Product sales 13,449 4,642 30,566 10,956 Contract revenues 624 106 2,044 426 Grant and government sponsored research revenue 4 619 13 1,868 Total revenues 14,077 5,367 32,623 13,250 Costs and operating expenses: Cost of product sales 7,494 2,768 16,625 6,433 Research and development 4,037 3,861 11,531 11,430 Selling, general and administrative 3,984 2,646 11,485 8,364 Expense contingency for patent related matter -- -- 1,264 -- Collaboration profit sharing 1,474 -- 2,506 -- Total costs and operating expenses 16,989 9,275 43,411 26,227 Loss from operations (2,912) (3,908) (10,788) (12,977) Other expenses, net (3) 7 15 (34) Net loss $(2,915) $(3,901) $(10,773) $(13,011) Basic and diluted net loss per share $(0.07) $(0.11) $(0.26) $(0.40) Shares used in computing basic and diluted net loss per share 41,889 33,985 40,775 32,596 CEPHEID CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands) September 30, December 31, 2004 2003 ASSETS (unaudited) (1) Current assets: Cash and cash equivalents $58,239 $18,510 Accounts receivable 9,091 3,504 Collaboration receivable -- 5,000 Inventory 6,760 5,088 Prepaid expenses and other current assets 687 650 Total current assets 74,777 32,752 Property and equipment, net 9,561 8,071 Intangible assets, net 31,244 47 Restricted cash 688 688 Total assets $116,270 $41,558 LIABILITIES AND SHAREHOLDERS` EQUITY Current liabilities: Accounts payable $5,524 $1,823 Accrued compensation 1,652 1,604 Accrued other liabilities 4,224 2,350 Current portion of deferred revenue 4,658 3,239 Current portion of license fees payable 10,89898 -- Current portion of equipment financing 2,129 1,897 Total current liabilities 29,085 10,913 Long-term portion of deferred revenue 6,667 8,095 Long-term portion of license fees payable 9,477 -- Equipment financing, less current portion 1,954 1,978 Deferred rent 576 497 Commitments Shareholders` equity: Preferred stock -- -- Common stock 151,923 92,694 Additional paid-in capital 7,513 7,501 Accumulated other comprehensive loss (45) (13) Accumulated deficit (90,880) (80,107) Total shareholders` equity 68,511 20,075 Total liabilities and shareholders` equity $116,270 $41,558 (1) The balance sheet at December 31, 2003 has been derived from the Company`s audited financial statements, which are included in the Company`s 2003 Annual Report on Form 10-K filed with the Securities and Exchange Commission.

Cepheid

[CaveModem [Mod]]

Guten Abend @all

auf Wunsch öffne ich diesen Thread wieder.

Gruß
CaveModem

[Ventrikel]

Antwort auf Beitrag Nr.: 31.362.507 von CaveModem am 31.08.07 22:45:34

Dankeschön!


Was tut sich bei Cepheid?

Der Grund für eine Reeröffnung ist kurz erklärt!
Nach Jahren des Aufbaus einer hochmodernen Biotechnologiebranche
vor allem in den Vereinigten Staaten ist es auch Cepheid gelungen,
die Brücken zu schlagen und hochklassige schnelle Diagnostik- und
Therapiesysteme zur Bekämpfung diverser aktueller bedrohlicher Infektionskrankheiten zu entwickeln.
Da erstmals nunmehr ein adäquater Vertrieb ins Laufen kommt, Umsätze und damit Gewinn generiert werden, schlägt sich das auch in einer hervorragenden Performance des Aktienkurs nieder- und die Produktpipeline ist bis Jahresende voll.
Zudem ist Cepheid ein klassischer Übernahmekandidat, aus der jüngsten Vergangenheit ist klar, welche Aufschläge in der
Pharma- und Biotechbranche bezahlt werden, um dem eigenen Konzern
auf die Sprünge zu helfen, bzw. eine Konkurrenten zu schlucken.

Die Umsätze im zentraleuropäischen Raum sind sehr gering, was verwunderlich ist, denn allein aufgrund des Chartbildes, ständiger Empfehlungen angesehener Analysten und großer Börsenbriefe
sowie des starken Wachstums von Cepheid und der ohnehin
boomenden Biotechnologiebranche ist hier enormes Kurspotential trotz eines schon stark gestiegenen Kurses enthalten.

Zudem war die nunmehr abelaufene Subprime-Krise, die fast jedes Marktsegment traf, spurlos an den meisten Biotech-Konzernen vorübergegangen, ein weiteres Indiz dafür, das auch in schwierigeren Zeiten mit einer sicheren Performance zu rechnen ist.

Diese paar Aspekte haben mich bewogen, hier zu investieren, wobei interessanterweise einige hundert Aktien den
Kurs bereits um mind. 20 Cent nach oben bewegten!! vor allem auch im Angesicht der Tatsache, dass Grossinvestoren und auch die Regierungen am Wachsen und Entwickeln neuer Diagnostika und Therapeutika sowieso interessiert sind, vor allem aus gesundheitsökonomischen Gründen.

Tja, nun hoffe ich, dass hier wieder gepostet wird, und sinnvoller Meinungsaustausch betrieben wird, nicht zuletzt auch deshalb,
weil hier ungeheures Potential steckt.

Mfg Ventrikel

[Ventrikel]

Antwort auf Beitrag Nr.: 31.363.362 von Ventrikel am 01.09.07 09:57:16

Na geil, ist denn hier überhaupt niemand und will sich
mit mir freuen, dass es hier stetig bergauf geht?

[donna hightower]

Antwort auf Beitrag Nr.: 31.419.750 von Ventrikel am 06.09.07 18:50:33

Hi Ventrikel,

ich bin schon lange bei CPHD mit an Board. Wie mir scheint, sind wir wohl die Einzigen....??????

Also dann freuen wir uns Beide wenigstens, zumal die Dynamik so stark zunimmt. Leider versaut uns der $ ein wenig diesen super Anstieg. Nun ja, wahrscheinlich lasse ich meine auch die nächsten 10 Jahre liegen, sofern nicht doch noch der grosse Crash kommt.

Gruß

dh

[Ventrikel]

Antwort auf Beitrag Nr.: 31.810.689 von donna hightower am 01.10.07 21:39:55

Hei!

Na endlich wer da! Unglaublich!

Bei W.O. sind so viele Supergescheite, aber dass die sich mal
Biotech-Werte anschauen, die nur steigen können , dafür langts eben
bei vielen nicht.
Mit Cepheid sind wir am richtigen Weg- laufen lassen.
Im übrigen sind wir wieder im Aktionär drin, das KZ halte ich aber
für lächerlich.
Und der Dollar erfängt sich zwar nicht wieder, aber dass er nicht weiter abstürzt, dafür wird Meister Bernanke schon sorgen, sei dir sicher!

Mfg Ventrikel

[NOBODY_III]

Antwort auf Beitrag Nr.: 31.831.671 von Ventrikel am 03.10.07 16:10:22

Ich hatte mir vor einigen Jahren ein paar Antiterror-Aktien zugelegt wie Digital Recorders (TBUS), Global E-Point (GEPT), Isonics (ISON) und mich in diesem Zusammenhang auch für Cepheid interessiert.

Möglicherweise hat man die Thematik besser in den Griff gekriegt. Das wäre die positive Seite. Gott sei Dank!

Die negative ist, daß TBUS, GEPT und ISON ein totaler Flop waren. Deshalb habe ich dann Cepheid auch nicht weiter verfolgt.

Man kann mit China Aktien leichter mehr verdienen, immer noch.

Soweit zur Info.

Wünsche Euch trotzdem noch viel Erfolg mit Cepheid.

mfG

[donna hightower]

Antwort auf Beitrag Nr.: 31.860.904 von NOBODY_III am 05.10.07 19:59:28

Hallo NOBy,

ich wünsche Dir alles Glück dieser Welt mit chin Aktien! Wenn Du immer sehr gewissenhafte Stopps setzst, kann Dir eigentlich nicht viel passieren, falls nicht zu Viele durch eine Tür wollen....

Mich erinnert dieses Szenario an die End-Neunziger.... "the sky is the limmit"

Gruß

dh

[donna hightower]

...... ja ist denn das díe Möglichkeit, dass sich wirklich kein Schw... in good old Germany für Cephaid interessiert??????

[donna hightower]

Antwort auf Beitrag Nr.: 32.954.233 von donna hightower am 05.01.08 20:43:29

@all,

in USA sind heute bereits 1.221.383 Aktien von CPHD gehandelt worden mit einem Kursplus von rd. 5 % und hier interessiert sich kein Mensch dafür......????

Ich stelle mal News aus e*trade rein:



7:03 AM Cepheid begins shipment of next generation GeneXpert Molecular Diagnostic Systems Briefing.com
Co announces that it has begun shipment of next generation GeneXpert Systems. The entire GeneXpert family of systems, including the new single module system GX-I, will now feature six-color optical capability that will enable detection of up to 60 individual targets in a single cartridge. The system ...
7:00 AM Cepheid Begins Shipment of Next Generation GeneXpert(R) Molecular Diagnostic Systems PR Newswire
Cepheid (Nasdaq: CPHD) today announced that the Company has begun shipment of next generation GeneXpert(R) Systems. The entire GeneXpert family of systems, including the new single module system GX-I, will now feature six-color optical capability that will enable detection of up to 60 individual ...
Headlines January 3, 2008

7:00 AM Cepheid to Present at the Needham Tenth Annual Growth Stock Conference PR Newswire
Cepheid (Nasdaq: CPHD) will present at the Needham Tenth Annual Growth Stock Conference on January 10 at 8:00 a.m. EST at the New York Palace Hotel. Sandra Finley, Vice President of Marketing, will provide an updated corporate overview.

[donna hightower]

Antwort auf Beitrag Nr.: 32.972.408 von donna hightower am 07.01.08 20:51:42

Nachfolgend die Veröffentlichung vom 07.01.08 im Volltext:

Falls die Homepage von Interesse sein sollte:

http://www.cepheid.com/Sites/cepheid/content.cfm?id=105" target="_blank" rel="nofollow ugc noopener">http://www.cepheid.com/Sites/cepheid/content.cfm?id=105

Cepheid Begins Shipment of Next Generation GeneXpert(R) Molecular Diagnostic Systems
1/7/2008 7:03:00 AM back to Press Releases

Hardware and software enhancements to the GeneXpert(R) System follow strong fourth quarter system placement momentum
SUNNYVALE, Calif., Jan 07, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Cepheid (Nasdaq: CPHD) today announced that the Company has begun shipment of next generation GeneXpert(R) Systems. The entire GeneXpert family of systems, including the new single module system GX-I, will now feature six-color optical capability that will enable detection of up to 60 individual targets in a single cartridge. The systems will also feature new software that enables Laboratory Information System (LIS) integration capabilities, linking any GX-I, GX-IV and GX-XVI System to healthcare institutions' central database for receiving, processing and storing test results.
The release of these enhancements follows a strong fourth quarter performance that saw 125 diagnostic GeneXpert System placements in Europe and the U.S. during the quarter. The system placements were comprised of 783 GeneXpert module installations.

"These new system enhancements are expected to further increase the utility of the GeneXpert System in processing data output and in achieving a high level of multiplex testing, which will be applied to infectious disease and oncology diagnostics," said Cepheid CEO John Bishop. "Additionally, these enhancements are expected to provide long-term benefits as our menu of tests grows, from infectious disease testing through oncology, and into broad-based genetic disease testing."

The new GeneXpert System six-color optics capability enables advanced multiplexing, making it possible to detect more molecular targets within a single test cartridge. The unique configuration of the GeneXpert cartridge allows for two reactions per test, which means that a total of 60 targets will be possible. The two-reaction capability also allows for reflex testing, in which the first test result indicates and automatically initiates a second related and potentially necessary diagnostic test. Reflex testing is particularly important in clinical applications where results can guide treatment decisions, such as for the detection of infectious disease where the first reaction tests for the organism and the reflex test identifies the specific strain susceptible to drug resistance.

All current GeneXpert-based tests, including Xpert(TM) MRSA, are compatible with the new six-color modules. Additionally, existing customers can expand their current GeneXpert Systems with the new six-color modules by adding to, or replacing, their four-color modules. The GeneXpert System software is capable of managing both four-color and six-color module types within the same GeneXpert System configuration.

The next generation GeneXpert Systems also include GeneXpert(R) Software 2.1, an easy-to-use application that synchronizes test data between any GeneXpert System and LIS. Upon completion of a test, the GeneXpert System may automatically upload test results to the LIS, providing healthcare professionals with rapid, actionable results as soon as they are available. By eliminating manual entries and paper-based workflows, the new GeneXpert

Systems improve the efficiency of transactions and may reduce the chance of transcription errors. Software upgrades are available to existing customers.

About Cepheid

Based in Sunnyvale, Calif., Cepheid (Nasdaq: CPHD) is an on-demand molecular diagnostics company that develops, manufactures, and markets fully-integrated systems for genetic analysis in the clinical, industrial and biothreat markets. The company's systems enable rapid, sophisticated genetic testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. The company's easy-to-use systems integrate a number of complicated and time-intensive steps, including sample preparation, DNA amplification and detection, which enable the analysis of complex biological samples in its proprietary test cartridges. Through its strong molecular biology capabilities, the company is focusing on those applications where rapid molecular testing is particularly important, such as identifying infectious disease and cancer in the clinical market; food, agricultural, and environmental testing in the industrial market; and identifying bio-terrorism agents in the biothreat market. See http://www.cepheid.com for more information.

This press release contains forward-looking statements that are not purely historical regarding Cepheid's or its management's intentions, beliefs, expectations and strategies for the future, including those relating to product performance and future market opportunities. Because such statements deal with future events, they are subject to various risks and uncertainties, and actual results could differ materially from the company's current expectations. Factors that could cause actual results to differ materially include risks and uncertainties such as those relating to: unforeseen manufacturing problems; customer and market acceptance of the product; the failure of products to perform as expected, whether due to manufacturing errors, defects or otherwise; the impact of competitive products and pricing; potentially lengthy sales cycles in some markets; reimbursement rates for the products; and underlying market conditions worldwide. Readers should also refer to the section entitled "Risk Factors" in Cepheid's Annual Report on Form 10-K for 2006 and in its most recent quarterly report on Form 10-Q, each filed with the Securities and Exchange Commission.

All forward-looking statements and reasons why results might differ included in this release are made as of the date of this press release, based on information currently available to Cepheid, and Cepheid assumes no obligation to update any such forward-looking statement or reasons why results might differ.

CONTACTS:
At the Company:
John L. Bishop
CEO, Cepheid
408-541-4191
[e-mail]

For Media Inquiries: For Investor Inquiries:

[donna hightower]

.... falls es von Interesse sein sollte:

Schlusskurs in USA: $ 26,83 gehandelte Aktien: 1.458.290

= über US-$ 39.000.000 !!!!

.... und ich bin im Thread "Alleinunterhalterin"

Gruß

dh

[donna hightower]

Antwort auf Beitrag Nr.: 32.973.313 von donna hightower am 07.01.08 22:04:32

@all,

innerhalb von 12 Minuten in USA bereits auf 27,54 $ und schon knapp 60.000 Stücke gehandelt, nur in Germany nichts.....??????


Ja, so ist es halt: Tritt ein Guru auf, geht auch hier der Handel los, oder: ohne Push läuft bei uns nichts!!!!!

Gruß

dh

[donna hightower]

Antwort auf Beitrag Nr.: 32.980.740 von donna hightower am 08.01.08 15:45:33

Guten Morgen @all,

wie ich sehe, schauen doch ein paar Leser auf der Seite vorbei!

Also gestriger Schlusskurs in USA: $ 29,50 (+ 10 %) mit 2.280.137 gehandelten Stücken!!!

In Deutschland nach langer Zeit mal wieder 290!!!! Stück gehandelt


Gruß

dh

[daitraider76]

Quartalszahlen am 1. Mai


Cepheid Schedules Teleconference and Webcast for First Quarter 2008 Results


SUNNYVALE, Calif., April 7, 2008 /PRNewswire-FirstCall/ -- Cepheid (News) will announce financial results for the first quarter 2008 after the markets close on Thursday, May 1, 2008. The announcement will be followed by a live conference call and webcast that afternoon at 4:30 p.m. Eastern Time.

[daitraider76]

SUNNYVALE, Calif., May 1 /PRNewswire-FirstCall/ -- Cepheid (Nasdaq: CPHD) today reported record revenue of $44.8 million for the first quarter of fiscal 2008, an increase of 76 percent over the first quarter of fiscal 2007. First quarter net loss was $1.9 million, or $(0.03) per share, on a GAAP basis; first quarter net income was $1.7 million, or $0.03 per diluted share, on a non-GAAP basis. Net loss in the first quarter of the prior year was $6.2 million, or $(0.11) per share on a GAAP basis, and $3.9 million, or $(0.07) per share, on a non-GAAP basis. Reconciliation between GAAP and non-GAAP results is provided at the end of this press release.

[daitraider76]

Antwort auf Beitrag Nr.: 34.014.588 von daitraider76 am 02.05.08 12:05:46

Cepheid auf Banken-Konferenzen

SUNNYVALE, Calif., May 6 /PRNewswire-FirstCall/ -- Cepheid (Nasdaq: CPHD - News) announced today that the Company will present at the following investor conferences:

-- The Robert W. Baird Growth Stock Conference on May 13 at 12:15 p.m. EDT
at The Four Seasons Hotel in Chicago

-- The Bank of America Healthcare Conference on May 14 at 3:40 p.m. EDT at
The Four Seasons Hotel in Las Vegas


John Bishop, Chief Executive Officer, and Andrew Miller, Senior Vice President, Chief Financial Officer, will provide a corporate overview at each conference.

http://biz.yahoo.com/prnews/080506/latu043.html?.v=101

[daitraider76]

Cepheid Signs Group Purchasing Contract With Premier Healthcare Alliance, One of the Largest U.S. Group Purchasing Organizations

SUNNYVALE, Calif., May 12 /PRNewswire-FirstCall/ -- Cepheid (News) today announced it has signed a group purchasing contract with Premier, Inc., one of the largest U.S. Group Purchasing Organizations (GPOs) with more than 1,500 participating hospitals and 42,000 other healthcare sites. In conjunction with this agreement, Cepheid has also signed a preferred vendor agreement with the Western North Carolina Health Network (WNCHN), a collaboration of 53 acute care hospitals that utilize Premier as their GPO. Under the terms of the contract, Premier and WNCHN customers can take advantage of Cepheid's GeneXpert(R) System and Xpert(TM) MRSA tests at pre-negotiated prices.

...
http://www.finanznachrichten.de/nachrichten-2008-05/artikel-…

[Longvest]

Hallo Donna Hightower,

ich kenne Cepeid seit ca. 7 Jahren und hab sie schon des öfteren gekauft und verkauft. Ursprünglich hatte ich sie erworben, weil sie zu Zeiten der amerikanischen Briefpost-Virenanschläge ein leicht transportables und sehr schnell einsetzbares Testgerät zum soforitgen Nachweis vorhandener Viren entwickelt hatten und sich dieses zu einem Verkaufsschlager entwickelte. Zwischenzeitlich ist Cepheid zu einem reinen Diagnostikunternehmen mit erstklassiger Entwicklung herangewachsen. Ich habe das Unternehmen bis heute ständig unter Beobachtung und bin auch in deren Emailverteiler eingeloggt. Nebenbei, ich hatte Cepheid teilweise für 5 Euro im Depot und hab sie dann für rund 9 Euro verkauft. Wenn ich gewusst hätte, daß sie mal auf fast 20 Euro raufschiesst, wäre ich natürlich drin geblieben. Anfang September kommen ja die Zahlen. Ich denke aber, daß sich hier im Moment nichts wesentliches tut. Dennoch halte ich das Unternehmen für ein gutes Langfristinvest.